MBRX
Moleculin Biotech, Inc. (MBRX) Business Model Analysis (2026)
Overall Score
Revenue Quality
No revenue is reported in the TTM data, so the business model is not yet demonstrating commercial scale.
Gross, operating, EBITDA, and net margins are all 0%, indicating no evidence of profitable revenue generation.
Profitability
TTM returns are deeply negative, including ROA of -1.44%, ROE of -8.17%, and ROIC of -2.42%.
Operating return on assets is -1.30% and return on tangible assets is -3.05%, showing the asset base is not producing earnings.
Cash Flow
Operating cash flow and free cash flow are both negative on a per-share basis, with free cash flow per share at -4.46.
Cash flow coverage metrics are extremely weak, reflecting continued cash burn and limited internal funding capacity.
Balance Sheet
The company has low reported debt relative to capital, with debt-to-capital at 2.46% and debt-to-assets at 1.38%.
Liquidity is tight, as the current ratio is 0.94 and working capital is negative at -$0.59M, but cash per share of $1.28 provides some near-term cushion.
Capital Efficiency
Capital efficiency remains poor, with return on invested capital at -2.42% and return on capital employed at -2.45%.
Asset turnover is 0 and working capital turnover is 0, indicating the asset base is not being used to generate sales.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Moleculin Biotech, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

